Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Zulresso Postmarket Commitment Hints At Easier Dosing In Postpartum Depression

Mar 20 2019

• By Derrick Gingery

Mother stressed and tired with her hands over her face

Related Content

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

Jan 30 2019

Sage May Be Forced To Simplify Brexanolone Dosing Regimen

Nov 09 2018

Sage's Brexanolone Could Be Transformative, But Only In Controlled Settings, US FDA Panel Says

Nov 02 2018

Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions

Oct 31 2018

US FDA's Internal Debate On Sage's Brexanolone Spills Into Open During Panel Review

Nov 07 2018

Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial

Mar 07 2019

Zulresso Is Sage’s First Step In Postpartum Depression Treatment

Mar 20 2019

Related Companies

Sage Therapeutics, Inc.

Johnson & Johnson

Additional Topics

United States Approvals Regulation FDA Neurology BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window